2024
68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention
REDONDO M, BUNDY B, PARIKH H, YOU L, TRIOLO T, FERRAT L, TEMPLEMAN E, TOSUR M, STECK A, GOTTLIEB P, ONENGUT-GUMUSCU S, RICH S, ORAM R, HEROLD K, KRISCHER J. 68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention. Diabetes 2024, 73 DOI: 10.2337/db24-68-or.Peer-Reviewed Original ResearchT1D riskAssociated with higher risk of progressionMarkers of response to treatmentNon-HLA single nucleotide polymorphismsEvaluate risk-benefit ratiosHigh risk of progressionGenetic risk scoreSingle nucleotide polymorphismsCox modelType 1 diabetes genetic risk scoreResponse to immunotherapyRisk of progressionIncreased T1D riskAssociated with higher riskResponse to treatmentRisk-benefit ratioInteraction termsT1D preventionType 1 diabetes preventionPrevent T1DTreatment armsHazard ratioScore 2Treated armClinical trials
2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal Of Medicine 2019, 381: 603-613. PMID: 31180194, PMCID: PMC6776880, DOI: 10.1056/nejmoa1902226.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedCD3 ComplexChildDiabetes Mellitus, Type 1Disease ProgressionDouble-Blind MethodExanthemaFemaleGlucose Tolerance TestHLA-DR3 AntigenHLA-DR4 AntigenHumansLymphocyte CountLymphopeniaMaleMiddle AgedProportional Hazards ModelsT-LymphocytesYoung AdultConceptsType 1 diabetesClinical type 1 diabetesTeplizumab groupPlacebo groupOral glucose tolerance testInsulin-producing beta cellsDouble-blind trialChronic autoimmune diseaseGlucose tolerance testRelatives of patientsRate of diagnosisHigh-risk participantsTransient lymphopeniaAdverse eventsHazard ratioHLA-DR3HLA-DR4Median timeClinical progressionAutoimmune diseasesExogenous insulinCD3 antibodyT cellsTeplizumabClinical disease